Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

14 Sept 2014

Abstract excerpt

BACKGROUND: Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents. Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines. Constructs evaluated in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Viral Infections and Outbreaks Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25225676
DOI: 10.1093/infdis/jiu511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical TrialPMID 25225676Read ↗

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challengeSemantic proximity Read ↗

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa virusesSemantic proximity Read ↗

Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and EbolaSemantic proximity Read ↗

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPsSemantic proximity Read ↗

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary ReportSemantic proximity Read ↗

Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccinesSemantic proximity Read ↗

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 ProteinsSemantic proximity Read ↗

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsSemantic proximity Read ↗

Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP)Semantic proximity Read ↗

Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP VaccineSemantic proximity Read ↗

Marek’s disease vaccines: Current status, and strategies for improvement and development of vector vaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.